COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Efficiency of Deep Transcranial Magnetic Stimulation on Patients With Mild Cognitive Impairment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT01464515
Recruitment Status : Not yet recruiting
First Posted : November 3, 2011
Last Update Posted : January 25, 2018
Information provided by (Responsible Party):

Brief Summary:
This is a first feasibility study in order to test if deep Transcranial Magnetic Stimulation (TMS) treatment with high frequency (10Hz) will improve the symptoms of patient MCI (Mild Cognitive impairment). The hypothesis of the study is that high frequency treatment with deep TMS will improve the daily functioning of patients who suffers from MCI.

Condition or disease Intervention/treatment Phase
Mild Cognitive Impairment Device: H-Coil Deep TMS Device: SHAM Coil TMS Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Other
Official Title: Feasibility Study in Order to Test the Efficiency of Deep TMS on Patient With MCI
Estimated Study Start Date : January 2019
Estimated Primary Completion Date : January 2021
Estimated Study Completion Date : January 2021

Arm Intervention/treatment
Active Comparator: Real TMS
this group will receive high frequency deep TMS treatment of 10HZ
Device: H-Coil Deep TMS
this group will receive high frequency treatment of deep TMS with 10Hz

Sham Comparator: SHAM TMS
this group will receive SHAM treatment of deep TMS
Device: SHAM Coil TMS
this group will receive SHAM treatment of deep TMS

Primary Outcome Measures :
  1. Mindstreams [ Time Frame: the test will be assessed on visit 17 which means 4 month from baseline ]
    Mindstreams test is designed to test the I.Q change of the patients from baseline

Secondary Outcome Measures :
  1. CDR - Clinical Dementia Rating [ Time Frame: the test will be assessed on visit 17 which means 4 month from baseline ]
    CDR test is designed to test the dementia severity of the patients from baseline

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   55 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Men and women 50-80 years of age.
  2. Self reporting of the patient about memory deterioration, without any damage of daily lify functioning.
  3. Scored of one standard deviation below the average (according to standardization of age and years of schooling) in the memory index and Mindstream test, without any major damage of other cognitive function)
  4. score >= 24 in MMSE (Mini Mental State Examination) test.
  5. Preserved Cognitive and executive functioning, without dementia according to DSM -IV
  6. Lack of other reason for memory deterioration like acute affect disorder or other neurological disorders, according to the doctor diagnosis.
  7. Score of maximum 0.5 in the Clinical Dementia Rating. in this test the score of the memory index will be 0.5 or 1, and not more then 1 point in two other index of this test.
  8. Capable and willing to provide informed consent.

Exclusion Criteria:

  1. Any other Axis I diagnosis as the primary diagnosis
  2. Any medications that can cause a risk of seizure. for instance, anti psychotic medication, high dosage of anti depression medication
  3. History of non tolerance for TMS treatment
  4. Diagnosis of Severe personality disorder according to DSM-IV
  5. current suicidal tendency
  6. Uncontrolled hypertension
  7. History of epilepsy, seizure, or heat convulsion
  8. History of epilepsy or seizure in first degree relatives
  9. History of head injury or stroke
  10. History of metal implants in the head (except dental fillings)
  11. History of surgery entailing metallic implants or known history of any metallic particles in the eye, implanted cardiac pacemaker, cochlear implants, use of neurostimulators, or any medical pumps
  12. History of drug or alcohol abuse
  13. Inadequate communication with examiner
  14. Participation in another clinical study, either concurrent with this trial or in the 3 months preceding it
  15. Inability to sign a consent form
  16. Women of childbearing potential and not using a medically accepted form of contraception when engaging in sexual intercourse

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01464515

Layout table for location contacts
Contact: Ellisa Ash, Dr. +97236973698

Layout table for location information
Ichilov Hospital, Neurological Department
Tel Aviv, Israel
Contact: Elissa Ash, Dr.    +97236973698   
Sponsors and Collaborators
Layout table for investigator information
Principal Investigator: Elissa Ash, Dr. Ichilov Hospital
Layout table for additonal information
Responsible Party: Brainsway Identifier: NCT01464515    
Other Study ID Numbers: P-0021
First Posted: November 3, 2011    Key Record Dates
Last Update Posted: January 25, 2018
Last Verified: January 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Brainsway:
Mild Cognitive Impairment, So Stated
Deep Transcranial Magnetic Stimulation
Additional relevant MeSH terms:
Layout table for MeSH terms
Cognitive Dysfunction
Cognition Disorders
Neurocognitive Disorders
Mental Disorders